Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 6 | 1 | — | — | — | 7 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 2 | — | — | — | 2 |
Rhabdomyosarcoma | D012208 | — | — | 1 | 1 | — | — | — | 1 |
Desmoplastic small round cell tumor | D058405 | — | — | 1 | 1 | — | — | — | 1 |
Triple negative breast neoplasms | D064726 | — | — | — | 1 | — | — | — | 1 |
Small cell lung carcinoma | D055752 | — | — | — | 1 | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Central nervous system neoplasms | D016543 | — | — | 2 | — | — | — | — | 2 |
Colorectal neoplasms | D015179 | — | — | 2 | — | — | — | — | 2 |
Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | — | — | — | 2 |
Non-small-cell lung carcinoma | D002289 | — | — | 2 | — | — | — | — | 2 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
Medulloblastoma | D008527 | — | — | 1 | — | — | — | — | 1 |
Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
Drug common name | PREXASERTIB |
INN | prexasertib |
Description | Prexasertib (LY2606368) is a small molecule checkpoint kinase inhibitor, mainly active against CHEK1, with minor activity against CHEK2. This causes induction of DNA double-strand breaks resulting in apoptosis. It was developed by Eli Lilly but the company announced in 2019 it was dropping prexasertib from active development, although clinical trials continue. Research continues into the efficacy of prexasertib in treatment of
acute myeloid leukemia, myelodysplastic syndrome, rhabdomyosarcoma, and medulloblastoma.
|
Classification | Small molecule |
Drug class | serine/threonine kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1cccc(OCCCN)c1-c1cc(Nc2cnc(C#N)cn2)n[nH]1 |
PDB | — |
CAS-ID | 1234015-52-1 |
RxCUI | — |
ChEMBL ID | CHEMBL3544911 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 820NH671E6 (ChemIDplus, GSRS) |